ArticleHaematologica2024
Gut microbiome alterations at acute myeloid leukemia diagnosis are associated with muscle weakness and anorexia.
Article in Haematologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 16 citations in OpenAlex.
- Inclusion of Multi-Omic Biomarkers Improves Prediction Accuracy of Response, Relapse, and Overall Survival in Acute Myeloid Leukemia Patients Receiving High-Intensity Induction Chemotherapy.Cancer medicine · 2026Article
- The role of the microbiota in hematological malignancies: A narrative review of mechanisms and therapeutic potential.New microbes and new infections · 2026Review
- Acute myeloid leukemia and gut microbiome: bidirectional effects and opportunities for intervention.Annals of hematology · 2026Review
- Micheliolide ameliorates colon cancer cachexia by modulating gut microbiota-immune signaling via Phocaeicola vulgatus enrichment.Microbiome · 2026Article
- The microbial metabolome: remodeling the therapeutic landscape in hematologic malignancies.NPJ biofilms and microbiomes · 2026Review
- Gut Microbiota and Acute Myeloid Leukemia: State of the Art, Clinical Signals, and Translational Opportunities.Antibiotics (Basel, Switzerland) · 2026Review
- Changes in levels of endocannabinoidome mediators in mice with cancer cachexia: links with steatosis and gut microbial dysbiosis.BJC reports · 2026Article
- Review
- The gut-bone marrow axis in acute leukemia: an evidence-graded review of microbiota-immune crosstalk and therapeutic implications.Frontiers in cellular and infection microbiology · 2026Review
- Lowered Abundance of Gut Bacteriophage Species Is Associated With Human Cancer Cachexia.Journal of cachexia, sarcopenia and muscle · 2026Article
- Therapeutic ecology of the fiber-microbiota-barrier axis in leukemia: resilience, immune recovery and pharmacomicrobiomics.Frontiers in microbiology · 2026Review
- The oral-gut-brain axis: how periodontitis influence depression.Frontiers in microbiology · 2026Review
- Host-microbiome interactions in leukemia: mechanisms, treatment response, and clinical implications.Frontiers in cellular and infection microbiology · 2026Review
- Microbiome dysbiosis and chemotherapy resistance in acute myeloid leukemia (AML).NPJ biofilms and microbiomes · 2025Review
- Review
- Genetically Predicted Gut Microbiota and Host Metabolites Mediate the Causal Link Between Dietary Factors and Acute Myeloid Leukemia.Food science & nutrition · 2025Article
- The gut microbiome and dietary fibres: implications in obesity, cardiometabolic diseases and cancer.Nature reviews. Microbiology · 2025Review
- Microbiome Modulation in Pediatric Leukemia: Impact on Graft-Versus-Host Disease and Treatment Outcomes: A Narrative Review.Children (Basel, Switzerland) · 2025Review
- Species-level taxonomic characterization of gut microbiota in HIV-infected individuals.Frontiers in microbiology · 2025Article
- Significant changes in gut microbiota and SCFAs among patients with newly diagnosed acute myeloid leukemia.Frontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 7 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiota makes critical contributions to host homeostasis, and its role in the treatment of acute myeloid leukemia (AML) has attracted attention. We investigated whether the gut microbiome is affected by AML, and whether such changes are associated with hallmarks of cachexia. Biological samples and clinical data were collected from 30 antibiotic- free AML patients at diagnosis and matched volunteers (1:1) in a multicenter, cross-sectional, prospective study. The composition and functional potential of the fecal microbiota were analyzed using shotgun metagenomics. Fecal, blood, and urinary metabolomics analyses were performed. AML patients displayed muscle weakness, anorexia, signs of altered gut function, and glycemic disorders. The composition of the fecal microbiota differed between patients with AML and control subjects, with an increase in oral bacteria. Alterations in bacterial functions and fecal metabolome support an altered redox status in the gut microbiota, which may contribute to the altered redox status observed in patients with AML. Eubacterium eligens, reduced 3-fold in AML patients, was strongly correlated with muscle strength and citrulline, a marker of enterocyte mass and function. Blautia and Parabacteroides, increased in patients with AML, were correlated with anorexia. Several bacterial taxa and metabolites (e.g., Blautia, Prevotella, phenylacetate, and hippurate) previously associated with glycemic disorders were altered. Our work revealed important perturbations in the gut microbiome of AML patients at diagnosis, which are associated with muscle strength, altered redox status, and anorexia. These findings pave the way for future mechanistic work to explore the function and therapeutic potential of the bacteria identified in this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.